Literature DB >> 12788905

Endocrine and metabolic responses to long-term monotherapy with the antiepileptic drug valproate in the normally cycling rhesus monkey.

Michel Ferin1, Martha Morrell, Ennian Xiao, Lisa Kochan, Fang Qian, Thomas Wright, Mark Sauer.   

Abstract

An association between epilepsy and reproductive disturbances with an apparent increase in a polycystic ovarian syndrome (PCOS) has been reported. Whether this association can be attributed to epilepsy itself or is related to antiepileptic drug therapy, in particular valproate (VPA), remains controversial. We studied effects of a long-term VPA treatment on cycling monkeys, postulating that, if VPA monotherapy were to promote abnormal endocrine and metabolic parameters that are characteristic of PCOS, changes in cyclicity would be readily demonstrated. After a 2-month control, a 12- to 15-month VPA monotherapy was initiated in 7 regularly cycling rhesus monkeys. Overall mean levels of VPA were 88.7 +/- 4.0 (SE) microg/ml. Mean body weight increased progressively during VPA treatment from 8.5 +/- 0.5 kg before treatment to 9.6 +/- 0.7 kg in the last week of treatment (P < 0.05). Monkeys continued to have regular ovulatory menstrual cycles throughout VPA monotherapy. Length of the cycles was 28 +/- 0.58 d in control and 28.4 +/- 1.18 d in the last 3 months of VPA treatment. Follicular and luteal lengths and peak preovulatory estradiol and integrated luteal progesterone levels did not differ between control and treatment. Ovaries from VPA-treated monkeys showed histological evidence of ovulation, and none had characteristic features of PCOS. Endocrine PCOS markers, such as increased early follicular LH/FSH ratio and androgen levels were not different in control and VPA treatment cycles. LH and 17-hydroxyprogesterone responses to GnRH agonist challenges and the insulin response to glucose tolerance tests were similar in control and VPA groups. Lipid profiles were not affected by VPA treatment. The data indicate that a 12- to 15-month therapeutic exposure to VPA does not induce cyclic hormonal or morphological ovarian abnormalities or characteristics of the PCOS when administered to nonepileptic normally cycling nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788905     DOI: 10.1210/jc.2002-021614

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease.

Authors:  Cynthia L Harden
Journal:  Epilepsy Curr       Date:  2005 Jul-Aug       Impact factor: 7.500

2.  What Valproate Does and Doesn't Do.

Authors:  Cynthia L Harden
Journal:  Epilepsy Curr       Date:  2004-03       Impact factor: 7.500

3.  A review of bipolar disorder in adults.

Authors:  Donald M Hilty; Martin H Leamon; Russell F Lim; Rosemary H Kelly; Robert E Hales
Journal:  Psychiatry (Edgmont)       Date:  2006-09

4.  Systemic administration of AAV8-α-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression.

Authors:  Jennifer B Nietupski; Gregory D Hurlbut; Robin J Ziegler; Qiuming Chu; Bradley L Hodges; Karen M Ashe; Mark Bree; Seng H Cheng; Richard J Gregory; John Marshall; Ronald K Scheule
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

5.  Inhibitory effect of valproic acid on ovarian androgen biosynthesis in rat theca-interstitial cells.

Authors:  Senait Fisseha; Roberto Towns; Miyuki Harada; Helle Peegel; K M J Menon
Journal:  Endocrine       Date:  2009-12-15       Impact factor: 3.633

6.  Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies.

Authors:  Li Min; Wang Chunyan; Rong Biaoxue
Journal:  BMC Pediatr       Date:  2020-03-02       Impact factor: 2.125

7.  The anti-epileptic drug valproic acid (VPA) inhibits steroidogenesis in bovine theca and granulosa cells in vitro.

Authors:  Claire Glister; Leanne Satchell; Anthony E Michael; Andrew B Bicknell; Philip G Knight
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

8.  Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy.

Authors:  Mythili Ayyagari; Sita Ramu Chitela; Venkateswarlu Kolachana
Journal:  Ann Indian Acad Neurol       Date:  2012-04       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.